Sarepta Therapeutics Inc. (NASDAQ:SRPT) was upgraded by stock analysts at Jefferies Group from an “underperform” rating to a “hold” rating in a research note issued on Monday. The brokerage presently has a $50.00 price objective on the stock. Jefferies Group’s price target indicates a potential downside of 10.28% from the company’s previous close.

Other analysts have also recently issued reports about the stock. Piper Jaffray Cos. restated a “sell” rating and issued a $6.00 price target on shares of Sarepta Therapeutics in a report on Saturday, June 4th. Oppenheimer Holdings Inc. reiterated a “buy” rating and issued a $60.00 target price on shares of Sarepta Therapeutics in a research note on Sunday, July 17th. Wedbush reiterated a “neutral” rating and issued a $14.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, May 25th. SunTrust Banks Inc. reiterated a “reduce” rating on shares of Sarepta Therapeutics in a research note on Friday, May 27th. Finally, William Blair upgraded shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $88.00 target price for the company in a research note on Monday. Two analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $51.01.

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT) opened at 55.73 on Monday. The company’s market capitalization is $2.67 billion. The firm has a 50 day moving average of $28.17 and a 200-day moving average of $21.37. Sarepta Therapeutics has a 52-week low of $8.00 and a 52-week high of $56.80.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/19/sarepta-therapeutics-inc-srpt-upgraded-by-jefferies-group-to-hold-2.html

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same quarter last year, the company posted ($0.87) EPS. Equities analysts expect that Sarepta Therapeutics will post ($4.98) EPS for the current year.

In other news, CEO Edward M. Md Kaye sold 24,557 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the completion of the transaction, the chief executive officer now directly owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 10.90% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Teacher Retirement System of Texas raised its position in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock valued at $115,000 after buying an additional 724 shares during the period. Advisor Group Inc. bought a new stake in Sarepta Therapeutics during the second quarter worth about $154,000. Quantitative Systematic Strategies LLC bought a new stake in Sarepta Therapeutics during the second quarter worth about $211,000. National Planning Corp boosted its stake in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares in the last quarter. Finally, First Allied Advisory Services Inc. boosted its stake in Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock worth $245,000 after buying an additional 800 shares in the last quarter. 72.09% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.